SAN DIEGO, April 26, 2004 (PRIMEZONE) -- Cell Bio-Systems, Inc. (Pink Sheets:CBSI), a biotechnology company seeking to manufacture and distribute patented, disposable technologies for cosmetic surgery, biopsy, orthopedic surgery and other living tissue procedures, announced today that it has completed the development of its first set of production tools.
These tools will allow the manufacture of the company's flagship instrument, the Super-Luer, a patented connection system and the centerpiece component for the company's bio-device kits utilized in procedures ranging from liposuction and fat re-injections to gene therapy technologies and stem cell research.
The Super Luer will be adapted to manufacture the first affordable, disposable cannula, an enclosed tubular device, currently made from stainless steel, that looks much like a large needle and has been popularized by its use to insert or extract tissue during liposuction and collagen implant procedures. Though re-sterilized, steel cannulas are reused in hundreds of procedures, typically for as long as two years or more. Despite safety concerns and complications regularly ascribed to steel cannulas, no comparable, disposable device currently exists.
"A series of minor adjustments were made throughout the process until our teams were certain that the tools worked perfectly as designed," said Marc Pilkington, president and CEO of Cell-Bio-Systems. "The next step will involve the assembly of the Super Luer part with both coated and un-coated cannula stem configurations. We look forward to involving physicians in the product development process very shortly, with select doctors testing our products by July of this year."
The announcement comes after several months of development and improvements during which the production parts were assembled and repeatedly tested for fit, form and function, prior to final approval by Cell Bio-Systems management and design teams.
About Cell Bio-Systems
Based in San Diego, California, Cell Bio-Systems is the exclusive licensee of two patented syringe connection products that it plans to adapt as disposable devices for liposuction and other Living Tissue Management(tm) procedures. The company is developing an affordable, disposable product line that will fill this void in the cosmetic surgery and living tissue marketplace. The company's patented, groundbreaking technology will increase patient safety and enhance procedural outcomes. Most notably, Cell Bio-Systems devices can be adapted for a variety of procedures, ranging from fat transfers to biopsies to stem cell research. The company ultimately will develop a complete living tissue management system. For more information, please visit www.cellbiosystems.com.
Legal Notice Regarding Forward-Looking Statements: "Forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. CBSI disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions (including in the information technology and financial information industry), actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, and changes in our business strategies.